Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company's wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS).